News | July 22, 2014

NorthStar Medical Radioisotopes Breaks Ground for New Facility in Beloit, Wis.

Facility to support company’s work at University of Missouri Research Reactor to develop domestic source of molybdenum-99

July 22, 2014 — NorthStar Medical Radioisotopes broke ground on a new 50,000-square-foot facility in Beloit, Wis. When completed in late 2014, the facility will house the company’s headquarters and activities related to the production of the medical radioisotope molybdenum-99 (Mo-99).

Mo-99 is the parent isotope of technetium-99m (Tc-99m), the most widely used radioisotope in medical diagnostic imaging. Currently, nearly all Mo-99 is generated using highly enriched uranium (HEU) at aging facilities located outside of the United States, leading to product shortages and creating safety and national security concerns.

NorthStar is pursuing two non-uranium- and non-fission-based production processes that would help establish the first domestic source of Mo-99 since 1990. Both processes generate only a benign waste stream.

The new facility is phase one in the planned development of a 32-acre corporate campus for NorthStar. It will support the company’s work at the University of Missouri Research Reactor in Columbia, Mo., where NorthStar is developing a neutron capture process to generate Mo-99.

The facility will provide ancillary processes, packaging and products, including final assembly and testing of the proprietary RadioGenix intelligent isotope separation system. NorthStar will also move its company headquarters, currently located in Madison, Wis., to the facility.

“This groundbreaking is an exciting milestone for NorthStar Medical Radioisotopes and an important step toward achieving the goal of establishing a reliable and commercially viable domestic source of Mo-99,” said NorthStar President and CEO George P. Messina.

Phase two of the campus development project would see the building expanded; the site could accommodate a building as large as 110,000 square feet. Phase three would include construction of a linear accelerator facility for use in the second Mo-99-generation process that NorthStar is developing. A third building also could be constructed on the site in the future as the company continues to expand.

For more information: www.northstarnm.com

Related Content

ASRT Supports Radiopharmaceutical Reimbursement Bill
News | Radiopharmaceuticals and Tracers | August 02, 2019
The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) 3772, a measure...
NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility
News | Radiopharmaceuticals and Tracers | July 16, 2019
NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility
News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide, radiopharmaceutical...
Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 26, 2018 | Dave Fornell
February 8, 2018 — The U.S.
ARTMS Products Inc. and GE Healthcare Team Up to Expand Cyclotron-Produced Radioisotopes
News | Radiopharmaceuticals and Tracers | August 30, 2017
ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99 Irradiation...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a...
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the development of a new...
Overlay Init